Clinical Trial Update: Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study evaluating lamotrigine 25 mg tablets (two 25 mg tablets) under fasting conditions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• Lamotrigine (lamotrigine)

Snippet

Sponsor: IPCA Laboratories Ltd. | Conditions: Fasting State | Phase 1 | Status: COMPLETED